What can we expect from myeloid growth factors?
Bronchud
M H
MH
Department of Clinical Oncology, Hospital of San Pablo, Universitat Autonoma, Barcelona, Spain.
D004311:Double-Blind Method; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000627:therapeutic use*; D006801:Humans; D007970:Leukopenia / Q000517:prevention & control; D009369:Neoplasms / Q000188:drug therapy; D012313:RNA / Q000009:adverse effects; D011994:Recombinant Proteins / Q000627:therapeutic use
D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; D012313:RNA; D016178:Granulocyte-Macrophage Colony-Stimulating Factor